OMNI-LITE INDUSTRIES REPORTS THIRD QUARTER AND YEAR-TO-DATE FISCAL 2025 RESULTS CONFERENCE CALL FOR INVESTORS NOVEMBER 12, 2025, AT 11:00 AM EST GlobeNewswire November 10, 2025 Third Quarter Fiscal 2025 Highlights Revenue of US$4.0 million, a 7.0% and 16.8% Increase Over the Year Ago Period and Prior Quarter, respectively Adjusted EBITDA(1) of approximately US$325,000 Free Cash […]
Carbon Streaming Announces Financial Results for the Three and Nine Months Ended September 30, 2025 GlobeNewswire November 10, 2025 TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company“) today reported its financial results for the three and nine months ended September 30,
(NASDAQ:ETOR), Net Contribution grew by 28% year-over-year to $215 millionAssets Under Administration grew by 76% year-over-year to $20.8 billionFunded accounts grew by 16% year-over-year to 3.73 millionAnnounced a $150 million share repurchase program NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform,
Bitdeer Reports Unaudited Financial Results for the Third Quarter of 2025 GlobeNewswire November 10, 2025 – $169.7 million revenue, up 173.6% year-over-year– $43.0 million adjusted EBITDA, up from negative $7.9 million last year– Expanding and accelerating AI strategy across multiple initiatives– Achieved 41.2 EH/s of self-mining at the end of October, 2025– Commenced SEALMINER A3
EVgo Inc. Reports Third Quarter 2025 Results Total Revenues Increased 37% with Record Charging Network Revenue of $56 Million GlobeNewswire November 10, 2025 Total revenue of $92.3 million in the third quarter, representing an increase of 37% year-over-year. Charging network revenue totaled a record $55.8 million in the third quarter, an increase of 33% year-over-year,
(NASDAQ:TNYA), Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE(TM)-1 Trial of TN-401 for PKP2-associated
(NASDAQ:LFWD), MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets
(NASDAQ:SRTA), Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year period Medical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire November 10, 2025 Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with
Osisko Development Reports Third Quarter 2025 Results GlobeNewswire November 10, 2025 (All dollar amounts are expressed in Canadian dollars, unless stated otherwise) HIGHLIGHTS Q3 2025 (at September 30, 2025) ~$401.4 million in cash and cash equivalents Drawn ~$137.2 million (US$100.0 million) under the US$450 million Appian financing facility executed during the quarter Completed private placements